FilingReader Intelligence

Tiantan Bio abandons Paladin Biotech acquisition citing financial constraints

August 14, 2025 at 05:13 AM UTCBy FilingReader AI

Beijing Tiantan Biological Products Corporation has abandoned its planned acquisition of Paladin Biotech, citing insufficient cash reserves that would impact operations if the deal proceeded.

The company said a limited transaction timeline and risks associated with business integration given Paladin Bio's complex history also influenced the decision. China National Biotec Group will instead proceed with the acquisition.

Paladin Bio reported 2024 revenue of 2.65 billion yuan and net profit of 745 million yuan, with total assets of 9.25 billion yuan.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Beijing Tiantan Biological Products Corp publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →